BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Bcl-XL

April 2, 2015 7:00 AM UTC

Rodent studies suggest a selective Bcl-XL inhibitor could treat solid tumors without the hematological side effects of navitoclax. Chemical synthesis and in vitro binding studies identified a lead com...